Chenodeoxycholic Acid (CDCA) CAS 474-25-9 | Bile Acid Intermediate Factory
Chenodeoxycholic Acid (CDCA) CAS 474-25-9 | Bile Acid Intermediate Factory
Chenodeoxycholic Acid, CDCA powder, CAS 474-25-9, UDCA precursor, FXR endogenous ligand, bile acid intermediate, Shaanxi Sunrise
Source high-purity Chenodeoxycholic Acid (CDCA) CAS 474-25-9 directly from cGMP manufacturer. ≥98.0% HPLC bile acid intermediate for UDCA synthesis and FXR ligand R&D.
Send Inquiry
Description
cGMP STANDARD BILE ACID INTERMEDIATE
Chenodeoxycholic Acid (CDCA)
CAS No.: 474-25-9
Purity (HPLC)≥ 98.0% / ≥ 99.0%
Chemical Name3α,7α-Dihydroxy-5β-cholanic acid
Molecular FormulaC24H40O4
AppearanceWhite Crystalline Powder
💡 Quick Connection Notice: If your email link doesn't open, please directly send inquiries to: betty@pharma-sunrise.com
Scientific Overview & Manufacturing Excellence
We specialize in the contract manufacturing and stable market supply of high-purity Chenodeoxycholic Acid (CDCA). As a critical primary bile acid naturally extracted and refined, our CDCA serves as an indispensable structural building block and intermediate in the biochemical and pharmaceutical industries.
Utilizing a fully enclosed, advanced refinement process within cGMP-standardized facilities, we guarantee a product with high biological activity and zero harmful solvent residues. Each batch is stringently calibrated via High-Performance Liquid Chromatography (HPLC) to ensure a stable purity of ≥98.0% (with custom grades reaching ≥99.0%), seamlessly meeting the stringent requirements for downstream complex molecular assembly and industrial-scale pharmaceutical synthesis.
Pharmacological Profile & Core Industrial Applications
Core Precursor for UDCA Synthesis
Industrially, CDCA is the premier and most cost-effective upstream raw material for the large-scale commercial synthesis of Ursodeoxycholic Acid (UDCA). Our high-purity intermediate guarantees an unparalleled conversion efficiency and minimum impurity profile for global pharmaceutical manufacturing facilities.
Potent FXR Endogenous Ligand
In biochemical and pharmacological research, CDCA acts as the most potent naturally occurring endogenous ligand for the Farnesoid X Receptor (FXR). It is extensively utilized in R&D to modulate lipid metabolism, cholesterol homeostasis, and cellular signaling pathways relating to metabolic syndromes.
Synthesis of Bile Acid Derivatives
Beyond UDCA, it is a vital starting material for synthesizing advanced bile acid derivatives such as sodium taurochenodeoxycholate and other experimental drug candidates targeting liver and biliary tract diseases.
Technical Specifications & Quality Standards
| Product Identity | Chenodeoxycholic Acid (CDCA API Intermediate) |
|---|---|
| Chemical Nomenclature | 3α,7α-Dihydroxy-5β-cholanic acid |
| Testing Method & Purity | HPLC Analysis; ≥ 98.0% (Typical Bulk) / ≥ 99.0% (Custom) |
| Physicochemical Properties | • Appearance: White to off-white crystalline powder • Melting Point: 165–167 °C (Fluctuation ≤±1°C) • Loss on Drying: ≤ 1.0% • Residue on Ignition: ≤ 0.2% |
| Impurity Control | Single impurity ≤ 0.5%, Total impurities ≤ 1.0%. Verified via 1H NMR and MS analyses for structural authenticity. |
| Flexible Packaging Configurations | • R&D Scale: 1kg vacuum aluminum foil bag • Bulk Wholesale: 25kg sealed industrial fiber drum *Customized trial specifications are fully supported. |
| Storage & Shelf Life | Store tightly sealed in a dry environment at room temperature. Validity is 24 months under standard pharmaceutical storage protocols. |
Frequently Asked Questions (Procurement & Formulation)
Is this CDCA grade suitable for direct mass synthesis of UDCA?
Absolutely. Our CDCA is specifically refined as a high-purity pharmaceutical intermediate. With an assay of ≥98.0% and strictly controlled related substances (total impurities ≤1.0%), it delivers exceptional conversion yields and reduces downstream purification costs during commercial UDCA synthesis.
Can you provide structural identification data alongside the HPLC purity reports?
Yes. Every batch of our CDCA intermediate is released with a comprehensive Certificate of Analysis (COA). We provide full technical validation packages, including clear HPLC chromatograms, Mass Spectrometry (MS), and H-NMR spectral profiling to guarantee absolute structural authenticity.
Can you provide complete documents for overseas brand filing and customs clearance?
Yes. Manufactured under stringent ISO9001 and cGMP guidelines, we supply a complete technical package for our global clients. This includes COAs, Material Safety Data Sheets (MSDS), and required safety inspection certificates to fully support your border clearance.
Is this API available for direct clinical injection or patient prescription?
No. As clearly stated in our regulatory declaration, this product is a pharmaceutical intermediate intended strictly for industrial process development, formulation manufacturing, and institutional scientific research. It cannot be sold or used directly for human administration.
Shaanxi Sunrise Pharmaceutical Co., Ltd.
Senior Independent Site Operations Specialist: Betty
📧 Email: betty@pharma-sunrise.com|💬 WhatsApp: +86 18092760627